Cancer Fears Have Triggered Blood Pressure Drug Recalls for Months. Now Patients Are ‘Leery’
Cynthia Brown had been taking the drug valsartan for about two years when she learned last August that it had been recalled over fears of potential carcinogen contamination. Brown, a writer and patient advocate living near Cincinnati, had been prescribed valsartan to control shortness of breath related to primary pulmonary hypertension, but suddenly she had a whole new concern: cancer. “I’ve always been very conscientious about my health. I never dreamed I’d be on all these medications, and I’m real funny about what I take,” Brown, 65, says. “Valsartan has made me leery of all medication...
Source: TIME: Health - January 29, 2019 Category: Consumer Health News Authors: Jamie Ducharme Tags: Uncategorized Drugs healthytime Source Type: news

Torrent Recalls Six More Lots of Tainted Losartan Tablets Torrent Recalls Six More Lots of Tainted Losartan Tablets
The company has recalled a total of 16 lots of losartan potassium and hydrochlorothiazide combination tablets because of the presence of a probable carcinogen.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 24, 2019 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

UPDATED: Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP and Losartan Potassium and Hydrochlorothiazide Tablets, USP
Torrent Pharmaceuticals Limited is expanding its voluntary recall from 10 lots of Losartan potassium tablets USP to include 6 lots of Losartan potassium and hydrochlorothiazide tablets, USP, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 22, 2019 Category: Food Science Source Type: news

Antihypertension drug losartan may improve treatment of ovarian cancer
(Massachusetts General Hospital) A new study from a Massachusetts General Hospital research team has found that the hypertension drug losartan, which targets the angiotensin signaling pathway, may improve the effectiveness of chemotherapy agents used to treat ovarian cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 15, 2019 Category: Cancer & Oncology Source Type: news

Heart Drug Recall Expanded Again
(CNN) — The recall of popular heart drugs has expanded yet again. The US Food and Drug Administration said Thursday that Torrent Pharmaceuticals has added eight additional lots of losartan potassium tablets to its recall list. Losartan potassium is a drug used to control high blood pressure. It is also used to treat kidney disease in patients with diabetes. This recall includes 30-, 90- and 1,000-count bottles of 100-milligram tablets; 30-, 90- and 1,000-count bottles of 50-milligram tablets; and 90-count bottles of 25-milligram tablets. Torrent is recalling only these particular losartan potassium tablets. Tests fou...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - January 4, 2019 Category: Consumer Health News Authors: Health – CBS Boston Tags: Health News CNN Recall Valsartan Source Type: news

Heart drug recall expanded again
The recall of heart drugs has expanded again to include Torrent Pharmaceuticals losartan potassium and Aurobindo Pharma USA Inc. drugs containing valsartan. (Source: CNN.com - Health)
Source: CNN.com - Health - January 4, 2019 Category: Consumer Health News Source Type: news

Torrent Pharmaceuticals Limited Expands Voluntary Nationwide Recall of Losartan Potassium Tablets, USP
Torrent Pharmaceuticals Limited is expanding its voluntary recall from 2 lots of Losartan potassium tablets USP to a total of 10 lots, to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. Torrent is only recalling lots of losartan-containing products that contain N-nitrosodiethylamine (NDEA) above the acceptable daily intake levels released by the FDA. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 3, 2019 Category: Food Science Source Type: news

Blood pressure medication recalled after cancer-causing chemical found
FDA announces that Torrent Pharmaceuticals Limited is voluntarily recalling two lots of Losartan potassium tablets (Source: Health News: CBSNews.com)
Source: Health News: CBSNews.com - December 23, 2018 Category: Consumer Health News Source Type: news

Torrent Pharma Recalls Two Lots of Tainted Losartan Tablets Torrent Pharma Recalls Two Lots of Tainted Losartan Tablets
In the next chapter of the ongoing tainted-ARB saga, the recall covers certain lots of losartan potassium tablets found to contain what were called trace amounts of the probable carcinogen NDEA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 21, 2018 Category: Consumer Health News Tags: Cardiology News Source Type: news

Torrent Pharmaceuticals Limited Issues Voluntary Nationwide Recall of Losartan Potassium Tablets, USP
Torrent Pharmaceuticals Limited is voluntarily recalling 2 lots of Losartan potassium tablets, USP to the consumer level due to the detection of trace amounts of an unexpected impurity found in an active pharmaceutical ingredient (API) manufactured by Hetero Labs Limited. The impurity detected in the API is N-nitrosodiethylamine (NDEA), which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen as per International Agency for Research on Cancer (IARC) classification. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 20, 2018 Category: Food Science Source Type: news

Medical News Today: Losartan potassium: Uses and warnings
This article provides an overview of the benefits, effectiveness, side effects, and warnings associated with losartan potassium. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 18, 2018 Category: Consumer Health News Tags: Hypertension Source Type: news

Another Tainted'Sartan' Recalled for Impurity Another Tainted'Sartan' Recalled for Impurity
Sandoz, along with FDA, has recalled one lot of losartan potassium hydrochlorothiazide tablets because of the presence of the probable human carcinogen NDEA.News Alerts (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 16, 2018 Category: Consumer Health News Tags: Cardiology News Alert Source Type: news

Losartan Latest BP Drug Recalled for Contamination
NDEA is found naturally in certain foods, drinking water, air pollution, and industrial processes, and it may cause cancer, according to the International Agency for Research on Cancer. (Source: WebMD Health)
Source: WebMD Health - November 13, 2018 Category: Consumer Health News Source Type: news

3rd blood pressure drug, losartan, recalled in recent weeks over impurity
For the third time in recent weeks, a blood pressure medication has been recalled because it may have been contaminated with an agent linked to cancer. (Source: Health News - UPI.com)
Source: Health News - UPI.com - November 13, 2018 Category: Consumer Health News Source Type: news

Blood Pressure Drug Recall Expands Again; Meds May Be Tainted With Cancer-Causing Chemical
(CNN) — The US Food and Drug Administration says another heart medicine is being voluntarily recalled after tests showed that it was tainted with a potential cancer-causing chemical. The recall includes one lot of Sandoz’s losartan potassium hydrochlorothiazide 100 milligram/25 milligram tablets with the lot number JB8912. Patients use these drugs to keep their high blood pressure in check. The drug is being recalled because the active ingredient has tested positive for N-Nitrosodiethylamine or NDEA, a suspected human and animal carcinogen that is used in gasoline as a stabilizer for industry materials and as a...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - November 12, 2018 Category: Consumer Health News Authors: Health – CBS Boston Tags: Consumer Health News Local TV Valsartan Source Type: news

Sandoz recalls China-made blood pressure drug
Novartis said its Sandoz division is recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - November 12, 2018 Category: Pharmaceuticals Source Type: news

Sandoz Inc. Issues Voluntary Nationwide Recall of One Lot of Losartan Potassium and Hydrochlorothiazide Due to the Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient (API)
Sandoz Inc. is voluntarily recalling one lot of Losartan Potassium Hydrochlorothiazide Tablets, USP 100mg/25mg to the consumer level. This product is being recalled due to the trace amount of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Losartan, USP manufactured by Zhejiang Huahai Pharmaceutical Co. Ltd. Sandoz Inc. Losartan Potassium Hydrochlorothiazide product is manufactured by Lek Pharmaceuticals dd, Ljubljana, Slovenia. This impurity, which is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, has been classified as a probable human carcinoge...
Source: Food and Drug Administration - November 9, 2018 Category: Food Science Source Type: news

Novartis division Sandoz recalls one lot of blood pressure drug
Novartis said on Thursday its Sandoz division was recalling one lot of losartan tablets after finding traces of a probable carcinogen in the blood pressure drug. (Source: Reuters: Health)
Source: Reuters: Health - November 9, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

Black cumin prevents kidney damage
(Natural News) The extract of black cumin (Nigella sativa) can help treat kidney damage induced by unilateral ureteral obstruction (UUO). This was what a study, published in the journal Phytochemical Research, found. The researchers administered an intraperitoneal injection of losartan (15 mg/kg), captopril (30 mg/kg), 200 mg/kg of N. sativa extract (NS), and 400 mg/kg NS... (Source: NaturalNews.com)
Source: NaturalNews.com - October 26, 2018 Category: Consumer Health News Source Type: news

Losartan vs. Valsartan (Differences between Side Effects and Uses)
Title: Losartan vs. Valsartan (Differences between Side Effects and Uses)Category: MedicationsCreated: 9/21/2018 12:00:00 AMLast Editorial Review: 9/21/2018 12:00:00 AM (Source: MedicineNet Medications General)
Source: MedicineNet Medications General - September 21, 2018 Category: Drugs & Pharmacology Source Type: news

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to Product/Label Mix-Up
Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodium Tablets, USP 10mg, lot# MON17384 Exp. 12/31/2019, was prompted because a complaint of a sealed bottle labeled as Montelukast 10mg 30 ct found to contain 90 tablets of Losartan Potassium Tablets, USP 50mg (Source: Food and Drug Administration)
Source: Food and Drug Administration - September 7, 2018 Category: Food Science Source Type: news

Camber Pharmaceuticals, Inc. Issues Voluntary Nationwide Recall of Montelukast Tablets USP, 10mg 30Ct. due to product/label mix-up
PISCATAWAY, N.J., Sept. 6, 2018 -- (Healthcare Sales & Marketing Network) -- Camber Pharmaceuticals, Inc. is voluntarily recalling one single lot of Montelukast Sodium Tablets, USP 10mg, to the consumer level. This recall of one batch of Montelukast Sodiu... Biopharmaceuticals, FDA, Product Recall Camber Pharmaceuticals, Montelukast, Losartan (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - September 6, 2018 Category: Pharmaceuticals Source Type: news

Label Mix-Up Prompts Montelukast Recall Label Mix-Up Prompts Montelukast Recall
Pill bottles that are labeled as montelukast sodium tablets but actually contain the antihypertensive losartan potassium are being recalled.News Alerts (Source: Medscape Internal Medicine Headlines)
Source: Medscape Internal Medicine Headlines - August 31, 2018 Category: Internal Medicine Tags: Pulmonary Medicine News Alert Source Type: news

losartan (Cozaar)
Title: losartan (Cozaar)Category: MedicationsCreated: 12/31/1997 12:00:00 AMLast Editorial Review: 6/22/2018 12:00:00 AM (Source: MedicineNet High Blood Pressure General)
Source: MedicineNet High Blood Pressure General - June 22, 2018 Category: Cardiology Source Type: news

New findings about why losartan is effective in treating Marfan syndrome may reshape our thinking about patient management
(Elsevier) Progressive dilation of the aortic root is considered one of the most serious manifestations of Marfan syndrome. The antihypertensive losartan is one of the two medications recommended by current guidelines attenuate the progression of this aortic enlargement, but which medication works best is still controversial. A new report in The American Journal of Pathology confirms losartan's efficacy but finds that the underlying mechanism of action is different than previously thought, opening up new possibilities for improvements in Marfan syndrome management. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - February 9, 2018 Category: Biology Source Type: news

Hyzaar (Losartan Potassium-Hydrochlorothiazide) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 27, 2017 Category: Drugs & Pharmacology Source Type: news

Commercialization of Generics Impacts Adverse Event Rates
Adverse events up for generic users of losartan, valsartan, candesartan in month of commercialization (Source: Pulmonary Medicine News - Doctors Lounge)
Source: Pulmonary Medicine News - Doctors Lounge - October 4, 2017 Category: Respiratory Medicine Tags: Cardiology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Emergency Medicine, Nephrology, Neurology, Nursing, Pathology, Pharmacy, Pulmonology, Journal, Source Type: news

Cozaar (Losartan Potassium) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - July 8, 2016 Category: Drugs & Pharmacology Source Type: news

In newly diagnosed hypertension with OSA, adding CPAP augmented the benefits of losartan
In patients with new-onset hypertension and obstructive sleep apnea, continuous positive airway pressure (CPAP) therapy plus antihypertensive treatment with losartan led to reductions in systolic... (Source: Clinical Neurology News)
Source: Clinical Neurology News - March 4, 2016 Category: Neurology Source Type: news

In newly diagnosed hypertension with OSA, adding CPAP augmented the benefits of losartan
In patients with new-onset hypertension and obstructive sleep apnea, continuous positive airway pressure (CPAP) therapy plus antihypertensive treatment with losartan led to reductions in systolic... (Source: Family Practice News)
Source: Family Practice News - March 4, 2016 Category: Primary Care Source Type: news

Unichem gets USFDA nod for hypertension treatment tablets
The product is generic version of Merck Sharp & Dohme Corp's Cozaar tablets in the strength of 25 mg, 50 mg and 100 mg, Unichem said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 16, 2015 Category: Pharmaceuticals Source Type: news

Losartan Fails to Reduce LV Mass in HCM Patients: INHERITLosartan Fails to Reduce LV Mass in HCM Patients: INHERIT
The negative study does offer some good news, according to an editorial, in that losartan safely reduced blood pressure in patients with obstructive and nonobstructive HCM. Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - December 30, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news

Beta-Blocker, ARB Similarly Protective of Aorta in Marfan'sBeta-Blocker, ARB Similarly Protective of Aorta in Marfan's
There was no placebo in the trial that saw similar aortic-root dimension changes from treatment with atenolol or losartan. If standard therapy with atenolol helped, perhaps losartan did too? Heartwire (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 26, 2014 Category: Consumer Health News Tags: Cardiology News Source Type: news

AHA: Losartan Disappoints in Hypertrophic Cardiomyopathy (CME/CE)
(MedPage Today) -- ARB no better than placebo for reducing left ventricular hypertrophy. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - November 20, 2014 Category: Cardiology Source Type: news

The Marfan Foundation Comments on Study that Shows Losartan to be...
Provides New Option for Patients(PRWeb November 18, 2014)Read the full story at http://www.prweb.com/releases/MarfanTrial/11_18_2014/prweb12336271.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - November 20, 2014 Category: Pharmaceuticals Source Type: news

Losartan No Better Than Atenolol In Marfan's Syndrome
Beta-blockers have been the standard treatment for people with Marfan's syndrome, a rare inherited connective tissue disorder that affects about 1 in 5000 people. The goal of treatment is to prevent or slow down the dilation of the aorta and avoid aortic dissection, the main cause of death. In recent years, studies have raised the hope that losartan, an angiotensin receptor blocker, might be more effective than beta-blockers in slowing aortic enlargement. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - November 19, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Atenolol vs Losartan in Patients With Marfan SyndromeAtenolol vs Losartan in Patients With Marfan Syndrome
Drs Bowen and Connolly discuss the results of a landmark head-to-head comparison of losartan vs atenolol in patients with Marfan syndrome. Mayo Clinic (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 18, 2014 Category: Cardiology Tags: Cardiology Commentary Source Type: news

Heart Drug, Losartan, Falls Short of Promise in a Study
The new study found there was no difference in the aortic growth rate between those taking losartan and those taking the standard treatment. (Source: NYT Health)
Source: NYT Health - November 18, 2014 Category: Consumer Health News Authors: By GINA KOLATA Tags: Marfan Syndrome Heart Blood Pressure Placebos Source Type: news

Studies Indicate that Losartan may be an effective treatment option for Marfan syndrome
Losartan blocks the action of certain natural substances that tighten the blood vessels, allowing the blood to flow more smoothly and the heart to pump more efficiently. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - November 18, 2014 Category: American Health Source Type: news

Kidney Cancer Patients on ASI Antihypertensives Live LongerKidney Cancer Patients on ASI Antihypertensives Live Longer
Kidney cancer patients who were taking captopril, lisinopril, losartan, and similar drugs for hypertension lived significantly longer than those who were not. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 29, 2014 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news

Blood pressure drug may enhance cancer treatment
A new study reveals that a common class of drug used to control high blood pressure could enhance cancer treatment by improving delivery of chemotherapy drugs and oxygen through tumors. A clinical trial is already in progress as a result of the study. Writing about their work in the online journal Nature Communications, researchers from Massachusetts General Hospital (MGH), an affiliate of Harvard Medical School, describe how the angiotensin inhibitor losartan increased blood flow and improved chemotherapy drug outcomes in mice with breast and pancreatic cancer... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 3, 2013 Category: Consumer Health News Tags: Cancer / Oncology Source Type: news

Cancer patients may benefit from repurposed hypertension med
Use of existing, well-established hypertension drugs could improve the outcome of cancer chemotherapy by opening up collapsed blood vessels in solid tumors. In their report in the online journal Nature Communications, Massachusetts General Hospital (MGH) investigators describe how the angiotensin inhibitor losartan improved the delivery of chemotherapy drugs and oxygen throughout tumors by increasing blood flow in mouse models of breast and pancreatic cancer. A clinical trial based on the findings of this study is now underway... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - October 3, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Common blood pressure drug losartan (Cozaar) reduces aortic enlargement in Marfan syndrome
A common drug that is used to treat high blood pressure in the general population has been found to significantly reduce a dangerous and frequently fatal cardiac problem in patients with Marfan syndrome. Results of the COMPARE (COzaar in Marfan PAtients Reduces aortic Enlargement) study reveal that patients treated with losartan (Cozaar) had a significantly reduced rate of aortic enlargement after 3 years compared to patients who did not receive the treatment... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 4, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

ESC: Losartan Treatment Slows Aortic Dilation (CME/CE)
AMSTERDAM (MedPage Today) -- Aortic root dilation among Marfan's disease patients can be slowed by treatment with the angiotensin receptor blocker losartan (Cozaar), researchers said here. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - September 2, 2013 Category: Cardiology Source Type: news

Tall Order: Losartan Looks Promising in Marfan SyndromeTall Order: Losartan Looks Promising in Marfan Syndrome
The lead investigator for the COMPARE study says, since blood-pressure lowering is already recommended in this group, losartan could be recommended to these patients. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 2, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Tall order: Losartan looks promising in Marfan syndrome
The lead investigator for the COMPARE study says, since blood-pressure lowering is already recommended in this group, losartan could be recommended to these patients. (Source: theHeart.org)
Source: theHeart.org - September 2, 2013 Category: Cardiology Source Type: news

Diabetics Taking Certain Blood Pressure Drugs At Lower Risk Of Heart Disease
Two drugs, telmisartan and valsartan, which are used to reduce blood pressure in people with diabetes, are associated with a lower risk of hospitalization for heart attack, stroke or heart failure, according to a study published in CMAJ (Canadian Medical Association Journal). For people with type 2 diabetes, disease-related vascular illnesses are the main causes of death. Angiotensin-receptor blockers including telmisartan, valsartan, candesartan, irbesartan and losartan, are generally used interchangeably to control blood pressure... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 10, 2013 Category: Consumer Health News Tags: Hypertension Source Type: news